Update on the Regulation of LDTs: FDA, VALID Act, CLIA Modernization, and More
Sponsored by the ACMG Advocacy and Government Affairs Committee
May 21, 2024 | 2:00 – 3:00 pm ET
Educational Credits are not offered.
Description:
Join members of ACMG’s Advocacy and Government Affairs Committee and Policy Team to hear updates on potential changes to the regulation of laboratory-developed tests (LDTs) in the US. Speakers will provide updates on the current status of the FDA’s final rule on regulation of LDTs and its implementation. They will also provide updates on congressional involvement, including legislative efforts such as the VALID Act and CLIA Modernization.
Target Audience
All healthcare professionals.
Agenda
Michelle McClure, PhD – Intro & FDA update (15 minutes)
Marco Leung, PhD, FACMG – VALID Act (15 Minutes)
Sarah South, PhD, FACMG – CLIA Modernization (15 minutes)
Q&A (15 minutes)
Learning Objectives
At the conclusion of this session, participants should be able to:
- Summarize the current regulatory and legislative landscape of proposed policies that would change how LDTs are regulated.
- Assess the impact of the FDA rule on LDT regulation on clinical testing laboratories.
- Explore the remaining opportunities to block or overturn the FDA proposed rule on LDTs.